Finance

Lists
GKOS:NYSE
Glaukos Corp
$163.81
+1.48%
(+2.39) 1D
$163.81
0.00% (0.00)
After hours
Closed: Sep 18, 4:00:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GKOS...
Open
$160.60
High
$163.85
Low
$159.01
Mkt. cap
9.66B
Avg. vol.
664.10K
Volume
1.46M
52-wk high
$191.62
52-wk low
$73.16
EPS
-$3.26
Beta
0.76
Shares outstanding
58.98M
No. of employees
1K
Open
$160.60
High
$163.85
Low
$159.01
Mkt. cap
9.66B
Avg. vol.
664.10K
Volume
1.46M
52-wk high
$191.62
52-wk low
$73.16
EPS
-$3.26
Beta
0.76
Shares outstanding
58.98M
No. of employees
1K
News stories
From web sources and news partners
About Glaukos Corp
CEO-
Employees1.09K
Founded1998
HeadquartersAliso Viejo, California, United States
SectorMedical device
Websiteglaukos.com
Analyst ratings
Based on 13 analysts giving stock ratings to GKOS in the past 3 months
Strong buy
Buy
12
Hold
1
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for GKOS in the last 3 months.
Highest
Current $163.81
$225.00 (+37.35%)
Average
$193.58 (+18.17%)
Lowest
$165.00 (+0.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Stephan
Stifel Nicolaus
Buy
Maintained
$190.00
+16%
09/04/2026
Ryan Zimmerman
BTIG
Buy
Reiterated
$202.00
+23.3%
08/20/2026
Joanne Wuensch
Citi
Buy
Maintained
$225.00
+37.4%
08/14/2026
Adam Maeder
Piper Sandler
Buy
Maintained
$195.00
+19%
08/07/2026
Allen Gong
J.P. Morgan
Buy
Maintained
$200.00
+22.1%
08/04/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$185.00
+12.9%
07/31/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$195.00
+19%
07/30/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$215.00
+31.2%
07/30/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$195.00
+19%
07/30/2026
Steven Lichtman
William Blair
Buy
Maintained
-
-
07/30/2026
David Saxon
Needham
Buy
Reiterated
$201.00
+22.7%
07/30/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$178.00
+8.7%
07/30/2026
Unknown Analyst
UBS
Hold
Maintained
$172.00
+5%
07/30/2026
Patrick Wood
UBS
Hold
Maintained
$172.00
+5%
07/30/2026
Unknown Analyst
Jefferies
Buy
Maintained
$165.00
+0.7%
06/23/2026
David Roman
Goldman Sachs
Buy
Reiterated
$153.00
-6.6%
05/25/2026
Danielle Antalffy
UBS
Buy
Maintained
$150.00
-8.4%
01/28/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.14 / -$0.21
+33.54%beat
Revenue / Est. (USD)
185.61M / 150.91M
+22.99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
133.54M
143.12M
150.57M
185.61M
Cost of goods sold
28.83M
31.77M
33.34M
34.02M
Cost of revenue
28.83M
31.77M
33.34M
34.02M
Research and development expenses
38.07M
41.84M
44.14M
51.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
83.00M
96.51M
92.94M
116.06M
Operating expense
121.07M
138.35M
137.09M
167.36M
Total operating expenses
149.90M
170.12M
170.43M
201.38M
Operating income
-16.36M
-27.00M
-19.86M
-15.77M
Other non operating income
-
-
-
-
EBT including unusual items
-16.00M
-139.82M
-19.30M
-17.72M
EBT excluding unusual items
-16.00M
-26.95M
-19.30M
-16.22M
Income tax expense
234.00K
-6.16M
484.00K
656.00K
Effective tax rate
-1.46%
4.41%
-2.51%
-3.70%
Other operating expenses
-
-
-
-
Net income
-16.23M
-133.66M
-19.78M
-18.38M
Net profit margin
-12.15%
-93.39%
-13.14%
-9.90%
Earnings per share
-0.16
-0.28
-0.18
-0.14
Interest and investment income
2.55M
2.51M
2.43M
2.28M
Interest expense
-1.18M
-1.15M
-1.12M
-1.46M
Net interest expenses
1.38M
1.37M
1.31M
820.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.23M
-14.84M
-8.06M
-6.90M
Gain or loss from assets sale
20.00K
1.00K
103.00K
143.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps